INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 416m ago
HOUSE PTR16m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
HOUSE PTR/PurchaseVerified data

Gilbert Ray Cisneros, Jr. bought AGIO

Self · AGIOS PHARMACEUTICALS, INC. · Agios Pharmaceuticals, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
Aug 20, 2026
Disclosed
Sep 10, 2026
Disclosure timeline21 days from execution to publication · legal deadline 45 days
Aug 20 executedSep 10, 2026 disclosed

AGIO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
20/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing0 / 15

    Disclosed 21 days after execution (STOCK Act deadline: 45)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AGIO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    2
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M$197K
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    11
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$296K
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    500 sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    0
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M$13K
    500 sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    1
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    500 sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    8
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$56K
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M$37K
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    3
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    28
    Gilbert Ray Cisneros, Jr.DSelf
    AGIOAGIOS PHARMACEUTICALS, INC.
    Purchase
    		BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
    traded Mar 3, 2026
    		+35dHOUSE PTR

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20035390

    Timestamps

    Event (reported)
    Aug 20, 2026
    Published
    Sep 10, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 5, 14:01 UTC

    Extracted facts

    Filer
    Gilbert Ray Cisneros, Jr.
    Role
    Self
    Transaction
    PurchaseAs filed: “P”
    Asset
    Agios Pharmaceuticals, Inc. - Common Stock
    Ticker
    AGIO
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    Aug 20, 2026
    Notification date (reported)
    Sep 4, 2026
    Days from execution to publication
    21

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Gilbert Ray Cisneros, Jr. reported a purchase of Agios Pharmaceuticals, Inc. - Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Gilbert Ray Cisneros, Jr.bioguide:C001123
    Issuer
    AGIOS PHARMACEUTICALS, INC.cik:0001439222

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.